- Home
- SRE vs EW Comparison
SRE vs EW Comparison
Compare SRE & EW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SRE | EW |
|---|---|---|
| Founded | 1998 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Industrial Specialties |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.6B | 48.9B |
| IPO Year | 2008 | 1999 |
Fundamental Metrics
Financial Performance| Metric | SRE | EW |
|---|---|---|
| Price | $86.70 | $91.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $102.08 | $96.37 |
| AVG Volume (30 Days) | 2.7M | ★ 4.6M |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | ★ 2.84% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.58 | 1.07 |
| Revenue | ★ $13,702,000,000.00 | $6,067,600,000.00 |
| Revenue This Year | $6.42 | $13.39 |
| Revenue Next Year | N/A | $9.81 |
| P/E Ratio | ★ $54.75 | $86.50 |
| Revenue Growth | 3.92 | ★ 11.55 |
| 52 Week Low | $80.46 | $72.30 |
| 52 Week High | $101.04 | $96.29 |
Technical Indicators
Market Signals| Indicator | SRE | EW |
|---|---|---|
| Relative Strength Index (RSI) | 41.44 | 60.34 |
| Support Level | $84.92 | $81.88 |
| Resistance Level | $93.73 | $96.29 |
| Average True Range (ATR) | 1.78 | 2.10 |
| MACD | -0.07 | 0.68 |
| Stochastic Oscillator | 33.10 | 82.33 |
Price Performance
Historical ComparisonAbout SRE DBA Sempra
Sempra serves one of the largest utility customer bases in the United States. It distributes natural gas and electricity in Southern California and owns 80% of Oncor, a transmission and distribution business in Texas. Sempra Infrastructure Partners, 25% owned by Sempra, owns and operates liquefied natural gas facilities in North America and infrastructure in Mexico.
About EW Edwards Lifesciences Corporation
Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter aortic valves, and transcatheter mitral and tricuspid valve technologies. The firm derives about 60% of its total sales from outside the US.